Details of the Drug Reposition

General Information of This Drug (ID: DMC5MQD)

Drug Name
M2951   DMC5MQD
Synonyms
evobrutinib; Evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple sclerosis DISB2WZI 8A40 Phase 2 [1]
Rheumatoid arthritis DISTSB4J FA20 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Systemic lupus erythematosus DISI1SZ7 4A40.0 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)